Automated analyzers market seen growing to $7.6 billion by 2030

The automated analyzers market is projected to rise from $5.39 billion in 2025 to $5.79 billion in 2026, with growth tied to chronic disease prevalence, lab automation and faster diagnostic demand. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region through 2030.

Why it matters: - Automated analyzers are becoming more important as healthcare systems face higher testing volumes and a greater need for accurate, fast diagnostics. - The market’s projected rise signals continued investment in lab automation, especially for chronic disease management and high-throughput testing.

What happened: - The automated analyzers market was valued at $5.39 billion in 2025 and is projected to reach $5.79 billion in 2026. - The market is expected to grow to $7.6 billion by 2030. - The Business Research Company published the market study on July 27, 2026. - The report defines automated analyzers as laboratory instruments that perform repetitive analytical testing with minimal human input. - The company also released a free sample of the report and the full market report.

The details: - The market’s 2025 to 2026 growth reflects limits in manual and semi-automated testing, laboratory workforce constraints, rising clinical testing demand, expansion of diagnostic laboratories, and reliance on traditional analyzers. - The forecast through 2030 is supported by fully automated analyzers, AI and big data analytics, demand for rapid diagnostics, advances in genomics and proteomics research, and broader use of point-of-care testing. - Key trends include wider adoption of automated laboratory systems, higher demand for high-throughput sample processing, integration of multi-functional analyzers, and stronger accuracy and standardization in diagnostics and research. - Automated analyzers improve efficiency and accuracy by automating sample processing and handling large volumes of samples. - The systems are used in clinical laboratories and in chemical and hematological analyses. - Rising chronic disease prevalence is a major growth driver. - Aging populations, unhealthy lifestyles and urbanization are increasing cases of diabetes, cardiovascular disease and kidney disorders. - Automated analyzers support early detection, ongoing monitoring and treatment decisions for these conditions. - A June 2023 Kidney Research UK report said about 7.2 million people in the UK have chronic kidney disease, or more than 10% of the population. - The same report said 3.25 million are in advanced stages and 3.9 million are in early stages. - Kidney Research UK projected the number of UK chronic kidney disease cases will rise to 7.61 million by 2033. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing regional market over the next several years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market outlook points to a broader shift from manual lab work toward automated, data-driven diagnostics. - Regional growth patterns suggest mature markets will keep leading on scale, while faster healthcare investment in Asia-Pacific may drive the next wave of expansion.

What's next: - Market demand will likely track chronic disease burden, diagnostic volume growth and further adoption of AI-enabled laboratory tools. - Expansion in point-of-care testing and genomics research could create additional use cases for automated analyzers through 2030. - The Business Research Company provided contact details for expert inquiries through marketing@tbrc.info and its regional phone numbers. - The company also listed its LinkedIn and social media pages for follow-up information.